Service architecture
One page per therapy, from semaglutide to retatrutide
Search engines reward specificity. Instead of one crowded services page, this build gives every molecule, protocol, and hormone line its own indexable page with its own schema, FAQ, and lead form.
Example page. TupeloWeightLoss.com is a premium domain and turnkey website available for acquisition. Every service, price, and name shown is placeholder content the buying practice replaces with its own.
GLP-1 & metabolic
- SemaglutideWeekly GLP-1 therapy with the longest real-world track record.
- TirzepatideDual GIP/GLP-1 therapy for patients who want maximum appetite control.
- RetatrutideNext-generation triple-agonist therapy, framed for early-adopter searchers.
- LiraglutideDaily GLP-1 option for patients who tolerate smaller, steadier dosing.
- GLP-1 MicrodosingLow-dose maintenance protocols for patients at or near goal.
- Compounded GLP-1 OptionsHow compounded therapy is explained, priced, and sourced.
- Phentermine ProgramsTraditional appetite suppressant care with monitoring.
Peptide therapy
- Peptide TherapyThe hub page for every peptide protocol the clinic offers.
- BPC-157Recovery-focused peptide protocol for active patients.
- CJC-1295 / IpamorelinGrowth-hormone secretagogue protocol for body composition and sleep.
- SermorelinEntry-level GH peptide for energy, recovery, and sleep.
- TesamorelinTargeted protocol for stubborn visceral fat.
- AOD-9604Fat-metabolism peptide for plateau breaking.
Hormone therapy
Injectables & IV
Support & testing
- Metabolic Testing & Body CompositionInBody scans, RMR testing, and full metabolic labs.
- Nutrition & Protein CoachingCoaching built around protein targets and real Mississippi food.
- Muscle Preservation on GLP-1Strength and protein protocols to protect lean mass.
- Maintenance & Off-Ramp ProgramWhat happens after goal weight — the retention engine.
Every therapy line, already written
The buying practice edits names and pricing — the structure, schema, and internal linking are already in place.